<?xml version='1.0' encoding='utf-8'?>
<document id="26426352"><sentence text="The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes."><entity charOffset="55-66" id="DDI-PubMed.26426352.s1.e0" text="clopidogrel" /><entity charOffset="71-81" id="DDI-PubMed.26426352.s1.e1" text="cilostazol" /><pair ddi="false" e1="DDI-PubMed.26426352.s1.e0" e2="DDI-PubMed.26426352.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26426352.s1.e0" e2="DDI-PubMed.26426352.s1.e1" /></sentence><sentence text="The primary objective of the present study was to evaluate the pharmacokinetic and pharmacodynamic interactions between clopidogrel and cilostazol in relation to the CYP2C19 and CYP3A5 genotypes"><entity charOffset="120-131" id="DDI-PubMed.26426352.s2.e0" text="clopidogrel" /><entity charOffset="136-146" id="DDI-PubMed.26426352.s2.e1" text="cilostazol" /><pair ddi="false" e1="DDI-PubMed.26426352.s2.e0" e2="DDI-PubMed.26426352.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26426352.s2.e0" e2="DDI-PubMed.26426352.s2.e1" /></sentence><sentence text="" /><sentence text="In a randomized, three-way crossover study, 27 healthy subjects were administered clopidogrel (300 mg), cilostazol (100 mg) or clopidogrel + cilostazol orally"><entity charOffset="82-93" id="DDI-PubMed.26426352.s4.e0" text="clopidogrel" /><entity charOffset="104-114" id="DDI-PubMed.26426352.s4.e1" text="cilostazol" /><entity charOffset="127-151" id="DDI-PubMed.26426352.s4.e2" text="clopidogrel + cilostazol" /><pair ddi="false" e1="DDI-PubMed.26426352.s4.e0" e2="DDI-PubMed.26426352.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26426352.s4.e0" e2="DDI-PubMed.26426352.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26426352.s4.e0" e2="DDI-PubMed.26426352.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s4.e1" e2="DDI-PubMed.26426352.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26426352.s4.e1" e2="DDI-PubMed.26426352.s4.e2" /></sentence><sentence text=" Plasma concentrations of clopidogrel, cilostazol and their active metabolites (clopidogrel thiol metabolite, 3,4-dehydrocilostazol and 4″-trans-hydroxycilostazol), and adenosine diphosphate-induced platelet aggregation were measured for pharmacokinetic and pharmacodynamic assessment"><entity charOffset="26-37" id="DDI-PubMed.26426352.s5.e0" text="clopidogrel" /><entity charOffset="39-49" id="DDI-PubMed.26426352.s5.e1" text="cilostazol" /><entity charOffset="80-97" id="DDI-PubMed.26426352.s5.e2" text="clopidogrel thiol" /><entity charOffset="110-131" id="DDI-PubMed.26426352.s5.e3" text="3,4-dehydrocilostazol" /><entity charOffset="136-162" id="DDI-PubMed.26426352.s5.e4" text="4″-trans-hydroxycilostazol" /><entity charOffset="169-190" id="DDI-PubMed.26426352.s5.e5" text="adenosine diphosphate" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e0" e2="DDI-PubMed.26426352.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e0" e2="DDI-PubMed.26426352.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e0" e2="DDI-PubMed.26426352.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e0" e2="DDI-PubMed.26426352.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e0" e2="DDI-PubMed.26426352.s5.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e0" e2="DDI-PubMed.26426352.s5.e5" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e1" e2="DDI-PubMed.26426352.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e1" e2="DDI-PubMed.26426352.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e1" e2="DDI-PubMed.26426352.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e1" e2="DDI-PubMed.26426352.s5.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e1" e2="DDI-PubMed.26426352.s5.e5" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e2" e2="DDI-PubMed.26426352.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e2" e2="DDI-PubMed.26426352.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e2" e2="DDI-PubMed.26426352.s5.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e2" e2="DDI-PubMed.26426352.s5.e5" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e3" e2="DDI-PubMed.26426352.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e3" e2="DDI-PubMed.26426352.s5.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e3" e2="DDI-PubMed.26426352.s5.e5" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e4" e2="DDI-PubMed.26426352.s5.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s5.e4" e2="DDI-PubMed.26426352.s5.e5" /></sentence><sentence text="" /><sentence text="The area under the plasma concentration-time curve (AUC) of the active thiol metabolite of clopidogrel was highest in the CYP2C19 extensive metabolizers (EM) and lowest in the poor metabolizers (PM)"><entity charOffset="71-76" id="DDI-PubMed.26426352.s7.e0" text="thiol" /><entity charOffset="91-102" id="DDI-PubMed.26426352.s7.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26426352.s7.e0" e2="DDI-PubMed.26426352.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26426352.s7.e0" e2="DDI-PubMed.26426352.s7.e1" /></sentence><sentence text=" Cilostazol decreased the thiol metabolite AUC by 29% in the CYP3A5*1/*3 genotype [geometric mean ratio (GMR) 0"><entity charOffset="1-11" id="DDI-PubMed.26426352.s8.e0" text="Cilostazol" /><entity charOffset="26-31" id="DDI-PubMed.26426352.s8.e1" text="thiol" /><pair ddi="false" e1="DDI-PubMed.26426352.s8.e0" e2="DDI-PubMed.26426352.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26426352.s8.e0" e2="DDI-PubMed.26426352.s8.e1" /></sentence><sentence text="71; 90% confidence interval (CI) 0" /><sentence text="58, 0" /><sentence text="86; P = 0" /><sentence text="020] but not in the CYP3A5*3/*3 genotype (GMR 0" /><sentence text="93; 90% CI 0" /><sentence text="80, 1" /><sentence text="10; P = 0" /><sentence text="446)" /><sentence text=" Known effects of the CYP2C19 and CYP3A5 genotypes on the exposure of cilostazol and its metabolites were observed but there was no significant difference in the AUC of cilostazol and 3,4-dehydrocilostazol between cilostazol and clopidogrel + cilostazol"><entity charOffset="70-80" id="DDI-PubMed.26426352.s17.e0" text="cilostazol" /><entity charOffset="169-179" id="DDI-PubMed.26426352.s17.e1" text="cilostazol" /><entity charOffset="184-205" id="DDI-PubMed.26426352.s17.e2" text="3,4-dehydrocilostazol" /><entity charOffset="214-224" id="DDI-PubMed.26426352.s17.e3" text="cilostazol" /><entity charOffset="229-253" id="DDI-PubMed.26426352.s17.e4" text="clopidogrel + cilostazol" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e0" e2="DDI-PubMed.26426352.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e0" e2="DDI-PubMed.26426352.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e0" e2="DDI-PubMed.26426352.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e0" e2="DDI-PubMed.26426352.s17.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e0" e2="DDI-PubMed.26426352.s17.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e1" e2="DDI-PubMed.26426352.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e1" e2="DDI-PubMed.26426352.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e1" e2="DDI-PubMed.26426352.s17.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e1" e2="DDI-PubMed.26426352.s17.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e2" e2="DDI-PubMed.26426352.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e2" e2="DDI-PubMed.26426352.s17.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e2" e2="DDI-PubMed.26426352.s17.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e3" e2="DDI-PubMed.26426352.s17.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s17.e3" e2="DDI-PubMed.26426352.s17.e4" /></sentence><sentence text=" The inhibition of platelet aggregation from 4 h to 24 h (IPA4-24 ) following the administration of clopidogrel alone was highest in the CYP2C19 EM genotype and lowest in the CYP2C19 PM genotype (59"><entity charOffset="100-111" id="DDI-PubMed.26426352.s18.e0" text="clopidogrel" /></sentence><sentence text="05 ± 18" /><sentence text="95 vs" /><sentence text=" 36" /><sentence text="74 ± 13" /><sentence text="26, P = 0" /><sentence text="023)" /><sentence text=" However, the IPA of the CYP2C19 PM following co-administration of clopidogrel and cilostazol was comparable with that of the CYP2C19 EM and intermediate metabolizers (IM) only in CYP3A5*3/*3 subjects"><entity charOffset="67-78" id="DDI-PubMed.26426352.s25.e0" text="clopidogrel" /><entity charOffset="83-93" id="DDI-PubMed.26426352.s25.e1" text="cilostazol" /><pair ddi="false" e1="DDI-PubMed.26426352.s25.e0" e2="DDI-PubMed.26426352.s25.e0" /><pair ddi="false" e1="DDI-PubMed.26426352.s25.e0" e2="DDI-PubMed.26426352.s25.e1" /></sentence><sentence text="" /><sentence text="The additive antiplatelet effect of cilostazol plus clopidogrel is maximized in subjects with both the CYP2C19 PM and CYP3A5*3/*3 genotypes because of a lack of change of clopidogrel thiol metabolite exposure in CYP3A5*3/*3 as well as the highest cilostazol IPA in CYP2C19 PM and CYP3A5*3/*3 subjects"><entity charOffset="36-46" id="DDI-PubMed.26426352.s27.e0" text="cilostazol" /><entity charOffset="52-63" id="DDI-PubMed.26426352.s27.e1" text="clopidogrel" /><entity charOffset="171-188" id="DDI-PubMed.26426352.s27.e2" text="clopidogrel thiol" /><entity charOffset="247-261" id="DDI-PubMed.26426352.s27.e3" text="cilostazol IPA" /><entity charOffset="183-196" id="DDI-PubMed.26426352.s27.e4" text="thiol" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e0" e2="DDI-PubMed.26426352.s27.e0" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e0" e2="DDI-PubMed.26426352.s27.e1" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e0" e2="DDI-PubMed.26426352.s27.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e0" e2="DDI-PubMed.26426352.s27.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e0" e2="DDI-PubMed.26426352.s27.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e1" e2="DDI-PubMed.26426352.s27.e1" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e1" e2="DDI-PubMed.26426352.s27.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e1" e2="DDI-PubMed.26426352.s27.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e1" e2="DDI-PubMed.26426352.s27.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e2" e2="DDI-PubMed.26426352.s27.e2" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e2" e2="DDI-PubMed.26426352.s27.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e2" e2="DDI-PubMed.26426352.s27.e3" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e4" e2="DDI-PubMed.26426352.s27.e4" /><pair ddi="false" e1="DDI-PubMed.26426352.s27.e4" e2="DDI-PubMed.26426352.s27.e3" /></sentence><sentence text="" /></document>